Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217212 | 0.89 | NPY5R (0.52) | CTSKDRD2KCNA3KDM4DPARP1 | |
| SCHEMBL5115646 | 0.84 | CTSK (0.50) | CTSKDRD2KCNA3KDM4DPARP1 | |
| SCHEMBL5202966 | 0.83 | CTSK (0.53) | CTSKDRD2KCNA3KDM4DAAK1 | |
| SCHEMBL647174 | 0.83 | CTSK (0.48) | CTSKDRD2KCNA3KDM4DAAK1 | |
| SCHEMBL3486638 | 0.80 | GPR119 (0.58) | CHRM4 | |
| SCHEMBL5220499 | 0.80 | KDM4D (0.53) | CTSKDRD2KCNA3KDM4DAAK1 | |
| SCHEMBL21360311 | 0.79 | RET (0.49) | CTSKDRD2KCNA3KDM4DAAK1 | |
| SCHEMBL5216885 | 0.79 | CHRM4 (0.53) | CTSKDRD2KCNA3KDM4DPARP1 | |
| SCHEMBL14277283 | 0.79 | CTSK (0.44) | CTSKDRD2KCNA3KDM4DPARP1 | |
| SCHEMBL30976319 | 0.78 | EGLN2 (0.53) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399433-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
| EP-1399433-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002553-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | CTSK 174/4885DRD2 3746/4885KCNA3 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.